WallStSmart

Cincinnati Financial Corporation (CINF)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 270% more annual revenue ($46.72B vs $12.63B). CINF leads profitability with a 19.0% profit margin vs 16.7%. CINF appears more attractively valued with a PEG of 2.19. CINF earns a higher WallStSmart Score of 79/100 (B+).

CINF

Strong Buy

79

out of 100

Grade: B+

Growth: 9.3Profit: 8.0Value: 10.0Quality: 6.3
Piotroski: 6/9Altman Z: 1.59

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CINFUndervalued (+77.0%)

Margin of Safety

+77.0%

Fair Value

$709.49

Current Price

$155.45

$554.04 discount

UndervaluedFair: $709.49Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CINF5 strengths · Avg: 8.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

EPS GrowthGrowth
67.3%10/10

Earnings expanding 67.3% YoY

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
27.6%8/10

Strong operational efficiency at 27.6%

Revenue GrowthGrowth
21.8%8/10

Revenue surging 21.8% year-over-year

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

CINF2 concerns · Avg: 4.0/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CINF

The strongest argument for CINF centers on P/E Ratio, EPS Growth, Price/Book. Profitability is solid with margins at 19.0% and operating margin at 27.6%. Revenue growth of 21.8% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : CINF

The primary concerns for CINF are PEG Ratio, Altman Z-Score.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

CINF profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

CINF carries more volatility with a beta of 0.64 — expect wider price swings.

CINF is growing revenue faster at 21.8% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

CINF scores higher overall (79/100 vs 49/100), backed by strong 19.0% margins and 21.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cincinnati Financial Corporation

FINANCIAL SERVICES · INSURANCE - PROPERTY & CASUALTY · USA

Cincinnati Financial Corporation offers property and casualty insurance, its main business, through The Cincinnati Insurance Company, The Cincinnati Indemnity Company and The Cincinnati Casualty Company.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?